- Email: [email protected]
New soap products in India
FOCUS 90,000 tonnes/y to 150,000 tonnes/y, and to 250,000 tonnes in 2005. Norwest’s sales are expected to rise from A$8.5 M to around A$13.6 M in 2004. Chemical Week, 21 Apr 2004, 166 (13), (Website: http://www.chemweek.com)
Nanoporous materials demand to rise US demand for nanoporous materials such as zeolites and clays is expected to rise 4%/y, to $1.9 bn by 2007, according to a report from Freedonia Group. Zeolites are the largest segment of the market (approx 46%), and are forecast to grow 3.4%/y to 2007. Catalysts and detergent builders are the largest commercial application of zeolites. Chemical Week, 5 May 2004, 166 (15) (Website: http://www.chemweek.com)
APPLICATIONS Household & personal care Henkel taking over MAS detergents Henkel KGaA is expanding its detergents business in Mexico. It is taking over the MAS brand liquid detergents business from Master Products and its subsidiaries. The range includes MAS Color, MAS Ropa Fina, MAS Ropa Oscura and MAS Blancura. This will be complementary to Henkel’s present detergent activities in the country; Henkel has sold detergents in Mexico since 2000. European Chemical News, 5 Apr 2004, 80 (2094), 8
New water-soluble film for detergents MonoSol, a supplier of speciality water-soluble films, has launched a polyvinyl alcohol-based M-3030 that imparts faster solubility and lower price than rival films. M-3030 is intended for packaging powdered detergents and can handle alkaline products of as much as pH14. The product also allows detergent producers to utilize higher product concentrations since the user does not come in contact with the powder. European Plastics News, May 2004, 35
4
ON
S U R FA C TA N T S
Amway India launches SA8 Gelzyme Amway India has introduced a threein-one detergent under the brand name SA8 Gelzyme in a liquid concentrate formula. It reportedly pretreats, cleans and softens the clothes and has an improved fluorescent whitening agent which is meant for long-lasting results. Business Line, 8 Apr 2004, 11 (98 (supplement)), 4
New soap products in India Reckitt Benckiser India Ltd has introduced in milky white, saddle shaped form, Dettol Skincare Soap, with a special feminine fragrance. Elsewhere HLL has extended the range of Pears glycerine soap brand to Pears ‘germ shield’ variant. Pears range is now available in three variants of soap besides a face wash. Most Unilever subsidiaries source Pears brand from India, but the new introduction is meant primarily for the Indian market. HLL has also extended its Liril brand of toilet soap by introducing orange-coloured Liril Orange Fresh. In Apr 2002, the company launched blue Liril Icy Cool Mint. Liril Orange Fresh shower gel is also likely to be introduced, as shower gels of Liril Lime Fresh and Liril Icy Cool Mint variants are already available. Analysts say HLL is trying to revive the brand’s declining market share with new variants. The 109 year-old Lifebuoy soap has also been reintroduced in a new shape and formulation, which reportedly offers protection from germs, acne and infections on cuts and bruises. Business Line, 18 Mar 2004, 11 (77 (supplement)), 4; 25 Mar 2004, 11 (84), 6 & 1 Apr 2004, 11 (91), 6
Healthcare Discovery completes asthma trial, files application with FDA Discovery Laboratories Inc has successfully completed a Phase Ib clinical trial to evaluate the tolerability and lung deposition of its humanized lung surfactant, delivered as an inhaled aerosol, to treat patients with asthma. Results demonstrated that DSC-104 was safe and well tolerated, did not induce bronchospasm, and was deposited to both the central and peripheral regions of the lungs in the
mild-persistent asthmatic group and the healthy volunteers. The study was conducted at a leading pulmonary research facility in the UK. The company has also submitted a New Drug Application (NDA) to the US FDA for clearance to market Surfaxin for the prevention of Respiratory Distress Syndrome (RDS) in premature infants. The NDA filing is supported, in large part, by data from Discovery Laboratories’ two positive Phase III RDS clinical trials. It is also preparing a Marketing Authorization Application (MAA) to be filed with the European Medicines Evaluation Agency (EMEA) by mid2004 for Surfaxin for the prevention and treatment of RDS. Recently, the Committee for Proprietary Medicinal Products (CPMP) determined that Surfaxin qualified for evaluation through the Centralized Procedure, a more streamlined European regulatory review process that allows for a single application, evaluation and authorization for the entire European Union. Press release from: Discovery Laboratories Inc, 350, South Main Street, Suite 307, Doylestown, PA 18901, USA. Tel: +1 215 340 4699. Fax: +1 215 340 3940. E-mail: [email protected]. Website: http://www.discoverylabs.com (9 Mar, 14 Apr 2004)
Alliance Pharmaceutical, Nycomed collaboration PFC Therapeutics LLC, the wholly owned subsidiary of Alliance Pharmaceutical, has signed a collaboration agreement for Nycomed to develop and commercialize Oxygent in Europe. Oxygent (perflubron emulsion) is a patentprotected synthetic oxygen carrier based on its perfluorochemical and surfactant technologies that Alliance Pharmaceutical has evaluated in latestage clinical studies for avoidance of red blood cell transfusions during surgery. Nycomed will now be responsible for the remaining clinical and regulatory development, and future marketing of Oxygent within a broad European territory. The agreement includes an option for Nycomed to acquire Oxygent rights for China. PFC will be initially responsible for supply of Oxygent to Nycomed and will receive a royalty on Oxygent sales following commercialization. PFC retains JUNE 2004
Nanoporous materials demand to rise US demand for nanoporous materials such as zeolites and clays is expected to rise 4%/y, to $1.9 bn by 2007, according to a report from Freedonia Group. Zeolites are the largest segment of the market (approx 46%), and are forecast to grow 3.4%/y to 2007. Catalysts and detergent builders are the largest commercial application of zeolites. Chemical Week, 5 May 2004, 166 (15) (Website: http://www.chemweek.com)
APPLICATIONS Household & personal care Henkel taking over MAS detergents Henkel KGaA is expanding its detergents business in Mexico. It is taking over the MAS brand liquid detergents business from Master Products and its subsidiaries. The range includes MAS Color, MAS Ropa Fina, MAS Ropa Oscura and MAS Blancura. This will be complementary to Henkel’s present detergent activities in the country; Henkel has sold detergents in Mexico since 2000. European Chemical News, 5 Apr 2004, 80 (2094), 8
New water-soluble film for detergents MonoSol, a supplier of speciality water-soluble films, has launched a polyvinyl alcohol-based M-3030 that imparts faster solubility and lower price than rival films. M-3030 is intended for packaging powdered detergents and can handle alkaline products of as much as pH14. The product also allows detergent producers to utilize higher product concentrations since the user does not come in contact with the powder. European Plastics News, May 2004, 35
4
ON
S U R FA C TA N T S
Amway India launches SA8 Gelzyme Amway India has introduced a threein-one detergent under the brand name SA8 Gelzyme in a liquid concentrate formula. It reportedly pretreats, cleans and softens the clothes and has an improved fluorescent whitening agent which is meant for long-lasting results. Business Line, 8 Apr 2004, 11 (98 (supplement)), 4
New soap products in India Reckitt Benckiser India Ltd has introduced in milky white, saddle shaped form, Dettol Skincare Soap, with a special feminine fragrance. Elsewhere HLL has extended the range of Pears glycerine soap brand to Pears ‘germ shield’ variant. Pears range is now available in three variants of soap besides a face wash. Most Unilever subsidiaries source Pears brand from India, but the new introduction is meant primarily for the Indian market. HLL has also extended its Liril brand of toilet soap by introducing orange-coloured Liril Orange Fresh. In Apr 2002, the company launched blue Liril Icy Cool Mint. Liril Orange Fresh shower gel is also likely to be introduced, as shower gels of Liril Lime Fresh and Liril Icy Cool Mint variants are already available. Analysts say HLL is trying to revive the brand’s declining market share with new variants. The 109 year-old Lifebuoy soap has also been reintroduced in a new shape and formulation, which reportedly offers protection from germs, acne and infections on cuts and bruises. Business Line, 18 Mar 2004, 11 (77 (supplement)), 4; 25 Mar 2004, 11 (84), 6 & 1 Apr 2004, 11 (91), 6
Healthcare Discovery completes asthma trial, files application with FDA Discovery Laboratories Inc has successfully completed a Phase Ib clinical trial to evaluate the tolerability and lung deposition of its humanized lung surfactant, delivered as an inhaled aerosol, to treat patients with asthma. Results demonstrated that DSC-104 was safe and well tolerated, did not induce bronchospasm, and was deposited to both the central and peripheral regions of the lungs in the
mild-persistent asthmatic group and the healthy volunteers. The study was conducted at a leading pulmonary research facility in the UK. The company has also submitted a New Drug Application (NDA) to the US FDA for clearance to market Surfaxin for the prevention of Respiratory Distress Syndrome (RDS) in premature infants. The NDA filing is supported, in large part, by data from Discovery Laboratories’ two positive Phase III RDS clinical trials. It is also preparing a Marketing Authorization Application (MAA) to be filed with the European Medicines Evaluation Agency (EMEA) by mid2004 for Surfaxin for the prevention and treatment of RDS. Recently, the Committee for Proprietary Medicinal Products (CPMP) determined that Surfaxin qualified for evaluation through the Centralized Procedure, a more streamlined European regulatory review process that allows for a single application, evaluation and authorization for the entire European Union. Press release from: Discovery Laboratories Inc, 350, South Main Street, Suite 307, Doylestown, PA 18901, USA. Tel: +1 215 340 4699. Fax: +1 215 340 3940. E-mail: [email protected]. Website: http://www.discoverylabs.com (9 Mar, 14 Apr 2004)
Alliance Pharmaceutical, Nycomed collaboration PFC Therapeutics LLC, the wholly owned subsidiary of Alliance Pharmaceutical, has signed a collaboration agreement for Nycomed to develop and commercialize Oxygent in Europe. Oxygent (perflubron emulsion) is a patentprotected synthetic oxygen carrier based on its perfluorochemical and surfactant technologies that Alliance Pharmaceutical has evaluated in latestage clinical studies for avoidance of red blood cell transfusions during surgery. Nycomed will now be responsible for the remaining clinical and regulatory development, and future marketing of Oxygent within a broad European territory. The agreement includes an option for Nycomed to acquire Oxygent rights for China. PFC will be initially responsible for supply of Oxygent to Nycomed and will receive a royalty on Oxygent sales following commercialization. PFC retains JUNE 2004